WO1997013525A1 - Utilisation d'il-4 pour traiter le psoriasis - Google Patents

Utilisation d'il-4 pour traiter le psoriasis Download PDF

Info

Publication number
WO1997013525A1
WO1997013525A1 PCT/US1996/015749 US9615749W WO9713525A1 WO 1997013525 A1 WO1997013525 A1 WO 1997013525A1 US 9615749 W US9615749 W US 9615749W WO 9713525 A1 WO9713525 A1 WO 9713525A1
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
administered
human
dose
dosage
Prior art date
Application number
PCT/US1996/015749
Other languages
English (en)
Inventor
Edwin A. Peets
Jan E. De Vries
Maureen C. Howard
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to AU73836/96A priority Critical patent/AU7383696A/en
Publication of WO1997013525A1 publication Critical patent/WO1997013525A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4

Definitions

  • This invention relates to the use of lnterleukin-4 (IL-4) to treat psoriasis.
  • IL-4 lnterleukin-4
  • Psoriasis is a genetically determined disease of the skin and is universal in occurrence. In the United States and Northern Europe it affects from 1-2 percent of the population. The disease occurs as different morphologic types the most common of which is psoriasis vulgaris. The disease is characterized by cutaneous plaques which are erythematous, sharply demarcated with clear-cut borders, and which constantly produce large amounts of loosely adherent silvery scales. These scales are steadily shed from the skin. Most lesions are asymptomatic with scaling as the only finding; pruritus may occur in 20 percent of patients. Any body area may be involved with the disease, but lesions tend to occur most often on elbows, knees, scalp, and in the gluteal fold.
  • the major part of the pathophysiology of psoriasis is represented by an increase and rapid production of epidermal-keratinocytes-cells.
  • the keratinocyte turn-over time is 4-5 days as compared to a turn-over time of 28 days in normal epidermis.
  • the dermis pathologic changes include a proliferation of the papillary capillaries and a mononuclear cellular infiltrate comprised principally of T lymphocytes and dendritic cells.
  • Anthralin - this agent may be a primary irritant, stains clothing and skin, and is difficult to apply
  • Corticosteroids may produce cutaneous side effects including skin atrophy; more potent agents may suppress adrenal function; intensive therapy may result in tolerance to therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de traitement du psoriasis. Ce procédé consiste à administrer à l'homme une quantité efficace sur le plan thérapeutique d'IL-4 humain. On administre l'IL-4 de préférence par injection intracutanée au niveau de la zone atteinte par le psoriasis.
PCT/US1996/015749 1995-10-11 1996-10-08 Utilisation d'il-4 pour traiter le psoriasis WO1997013525A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73836/96A AU7383696A (en) 1995-10-11 1996-10-08 Use of il-4 to treat psoriasis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US508195P 1995-10-11 1995-10-11
US60/005,081 1995-10-11
US62477896A 1996-03-27 1996-03-27
US08/624,778 1996-03-27

Publications (1)

Publication Number Publication Date
WO1997013525A1 true WO1997013525A1 (fr) 1997-04-17

Family

ID=26673900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/015749 WO1997013525A1 (fr) 1995-10-11 1996-10-08 Utilisation d'il-4 pour traiter le psoriasis

Country Status (2)

Country Link
AU (1) AU7383696A (fr)
WO (1) WO1997013525A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028533A2 (fr) * 1999-10-19 2001-04-26 Kain Kevin C TRAITEMENT DE LA MALARIA PAR ACTIVATION DU PPARη-RXR ET REMONTEE DU CD36 DES MONOCYTES/MACROPHAGES, ET PRODUITS A CET EFFET
WO2023072877A1 (fr) * 2021-10-25 2023-05-04 Ellennbe Gmbh Composition pharmaceutique et kit comprenant une substance immuno-modulatrice pour traiter des maladies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007186A1 (fr) * 1989-11-21 1991-05-30 The University Of Melbourne Compositions et procedes anti-inflammatoires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007186A1 (fr) * 1989-11-21 1991-05-30 The University Of Melbourne Compositions et procedes anti-inflammatoires

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028533A2 (fr) * 1999-10-19 2001-04-26 Kain Kevin C TRAITEMENT DE LA MALARIA PAR ACTIVATION DU PPARη-RXR ET REMONTEE DU CD36 DES MONOCYTES/MACROPHAGES, ET PRODUITS A CET EFFET
WO2001028533A3 (fr) * 1999-10-19 2001-09-20 Kevin C Kain TRAITEMENT DE LA MALARIA PAR ACTIVATION DU PPARη-RXR ET REMONTEE DU CD36 DES MONOCYTES/MACROPHAGES, ET PRODUITS A CET EFFET
WO2023072877A1 (fr) * 2021-10-25 2023-05-04 Ellennbe Gmbh Composition pharmaceutique et kit comprenant une substance immuno-modulatrice pour traiter des maladies

Also Published As

Publication number Publication date
AU7383696A (en) 1997-04-30

Similar Documents

Publication Publication Date Title
Schwartz et al. Regression of experimental hamster cancer by beta carotene and algae extracts
US5376368A (en) Composition and method for treating inflammation
Cominelli et al. Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins.
KR100229974B1 (ko) 충실성종양을 치료하기위한 인터루킨-4의 조성물
US6086865A (en) Methods of treating angiogenesis-induced diseases and pharmaceutical compositions thereof
Watanabe et al. Inhibition of IL-1β-induced peripheral inflammation by peripheral and central administration of analogs of the neuropeptide α-MSH
US6558656B2 (en) Oral and topical compositions and methods related thereto in the treatment of acne
Pollmächer et al. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels
CA2069090A1 (fr) Compositions et methodes anti-inflammatoires
Aso et al. Prurigo pigmentosa successfully treated with minocycline
Pătraşcu et al. Ulcerated necrobiosis lipoidica to a teenager with diabetes mellitus and obesity
EP0225759B1 (fr) Compositions d'interféron
Elias et al. A controlled trial of topical propylthiouracil in the treatment of patients with psoriasis
US5178855A (en) Treatment of luekocyte dysfunction with GM-CSF
US5830454A (en) Method for treating cell mediated autoimmune disorders using interleukin-9
WO1997013525A1 (fr) Utilisation d'il-4 pour traiter le psoriasis
US5036050A (en) Compositions containing thymopentin for topical treatment of skin disorders
Bui et al. Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: effects on blood lymphocyte population in guinea pigs
France Roferon-A in combination with Tigason in cutaneous T-cell lymphomas
US5211947A (en) Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
Christophers et al. Identification of two endogenous neutrophil-activating peptides in psoriatic skin and inflammatory cells: C5ades arg and NAP
EP0772450A1 (fr) Procedes de traitement de troubles de saignement
GB2304342A (en) Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
JP4023863B2 (ja) Ｉｌ−６を含む血清尿酸値低下剤
US20070053872A1 (en) Treatment of wounds using il-17b

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97515083

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase